
    
      This phase Ia/IIa trial is designed to evaluate the safety and immunogenicity of different
      doses of the Inactivated SARS-CoV-2 Vaccine inoculated with different immunization schedules
      based upon the randomized, double-blind and placebo-controlled principle. A total of 942
      subjects aged 18 to 59 years old will be enrolled in the study, of which 192 and 750 will be
      enrolled for phase Ia and phase Ⅱa,respectively.The enrolled subjects in phase Ia receive two
      doses of low-, medium-, or high-dose of experimental vaccines or placebo at an interval of 14
      or 28 days, while the enrolled subjects in Phase Ⅱa receive two doses of medium, high-dose
      experimental vaccines or placebo at an interval of 14 or 28 days.
    
  